Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2019 08:36 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Advances Process Development for BXCL501 Thin Film Formulation

Automated, scalable process developed for manufacturing clinical and commercial supply BXCL501 thin film architecture is proprietary and flexible for combination therapies Multiple subjects treated...
April 29, 2019 17:17 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Host First Quarter 2019 Financial Results and Business Update

NEW HAVEN, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
April 03, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at Upcoming Investor Conferences in April

NEW HAVEN, Conn., April 03, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that the Company will deliver corporate overview presentations at both the H.C...
April 01, 2019 08:03 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting

Novel combination achieves synergistic anti-tumor effect and survival benefit Demonstrates BXCL701’s potential ability to bridge innate and adaptive immune systems Clinical Advisors Louis Weiner, MD...
March 25, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Files Clinical Trial Application for the Development of BXCL701 and Pembrolizumab in Neuroendocrine Prostate Cancer (tNEPC)

Expands global footprint for lead immuno-oncology program, BXCL701 Patient recruitment in US tNEPC study on-track; additional sites being activated Immuno-oncology Clinical Advisory Board expanded...
March 13, 2019 16:01 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at 29th Annual Oppenheimer Healthcare Conference

NEW HAVEN, Conn., March 13, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present...
March 11, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting

NEW HAVEN, Conn., March 11, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that it will present a late breaking poster featuring data from a preclinical...
March 07, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update

BXCL501 Pharmacokinetic (Bioavailability) and safety study on track to read out in second quarter 2019; initiation of Phase 2/3 Registration Trial expected in second half 2019 Human Proof of Concept...
March 05, 2019 16:01 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Participate in Upcoming Investor Conferences in March

NEW HAVEN, Conn., March 05, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present...
March 04, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer

Clinical partnership to evaluate triple combination of BioXcel Therapeutics’ BXCL701, Nektar’s NKTR-214 and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic cancer Merck KGaA,...